KEYLearning Hub
HNSCC KEYLEARNING HUB
Optimise the care of your M/uR HNSCC patients
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Welcome to the KEYLearning Hub in HNSCC, a peer-to-peer learning hub created with Oncologists to host an array of educational resources on the pathway, management and care of patients with metastatic or unresectable recurrent HNSCC with KEYTRUDA® (pembrolizumab).
Patient case studies
Choosing KEYTRUDA in M/uR HNSCC with CPS 1-19
Dr Caroline Brammer
First published on MSD Connect: September 2023
Treatment pathway
Abbreviations
HNSCC = Head And Neck Squamous Cell Carcinoma; M/uR = Metastatic Or Unresectable Recurrent.
Supporting documentation
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website
